 | • レポートコード：MRC2302E0042 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、230ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社では、2021年に6,883.36百万ドルであった世界の吸入＆点鼻スプレー式ジェネリック医薬品市場規模が、2022年に7,459.35百万ドルに達し、2027年には年平均成長率8.56%で11,272.80百万ドルまで成長すると予測しています。当調査レポートでは、吸入＆点鼻スプレー式ジェネリック医薬品の世界市場の現状について調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、競争状況などの構成でまとめております。セグメント分析では、疾患別（アレルギー性鼻炎、気管支喘息、COPD）、年齢層別（大人、子供（2～5歳）、子供（6～12歳））、部類別（アレルギーブロッカー、抗コリン作用、抗ヒスタミン剤、充血除去剤、その他）、経路別（吸入、鼻スプレー、局所用ローション）、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）の情報が含まれています。なお、当市場の主要企業には、AbbVie Inc.、Akorn, Inc.、Altaire Pharmaceuticals Inc.、Apotex Inc.、AstraZeneca PLC、Beximco Pharmaceuticals Ltd.、Catalent Pharma Solutions, Inc.、Chiesi Farmaceutici S.p.A.、Cipla Limited、Hikma Pharmaceuticals PLC、Nephron Pharmaceuticals Corporation、Perrigo Company PLC、Preferred Pharmaceuticals, Inc.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の吸入＆点鼻スプレー式ジェネリック医薬品市場規模：疾患別 - アレルギー性鼻炎における市場規模 - 気管支喘息における市場規模 - COPDにおける市場規模 ・世界の吸入＆点鼻スプレー式ジェネリック医薬品市場規模：年齢層別 - 大人の市場規模 - 子供（2～5歳）の市場規模 - 子供（6～12歳）の市場規模 ・世界の吸入＆点鼻スプレー式ジェネリック医薬品市場規模：部類別 - アレルギーブロッカーの市場規模 - 抗コリン作用の市場規模 - 抗ヒスタミン剤の市場規模 - 充血除去剤の市場規模 - その他部類の市場規模 ・世界の吸入＆点鼻スプレー式ジェネリック医薬品市場規模：経路別 - 吸入の市場規模 - 鼻スプレーの市場規模 - 局所用ローションの市場規模 ・世界の吸入＆点鼻スプレー式ジェネリック医薬品市場規模：地域別 - 南北アメリカの吸入＆点鼻スプレー式ジェネリック医薬品市場規模 アメリカの吸入＆点鼻スプレー式ジェネリック医薬品市場規模 カナダの吸入＆点鼻スプレー式ジェネリック医薬品市場規模 ブラジルの吸入＆点鼻スプレー式ジェネリック医薬品市場規模 … - アジア太平洋の吸入＆点鼻スプレー式ジェネリック医薬品市場規模 日本の吸入＆点鼻スプレー式ジェネリック医薬品市場規模 中国の吸入＆点鼻スプレー式ジェネリック医薬品市場規模 インドの吸入＆点鼻スプレー式ジェネリック医薬品市場規模 韓国の吸入＆点鼻スプレー式ジェネリック医薬品市場規模 台湾の吸入＆点鼻スプレー式ジェネリック医薬品市場規模 … - ヨーロッパ/中東/アフリカの吸入＆点鼻スプレー式ジェネリック医薬品市場規模 イギリスの吸入＆点鼻スプレー式ジェネリック医薬品市場規模 ドイツの吸入＆点鼻スプレー式ジェネリック医薬品市場規模 フランスの吸入＆点鼻スプレー式ジェネリック医薬品市場規模 ロシアの吸入＆点鼻スプレー式ジェネリック医薬品市場規模 … - その他地域の吸入＆点鼻スプレー式ジェネリック医薬品市場規模 ・競争状況 ・企業情報 |
The Global Inhalation & Nasal Sprays Generic Drugs Market size was estimated at USD 6,883.36 million in 2021 and expected to reach USD 7,459.35 million in 2022, and is projected to grow at a CAGR 8.56% to reach USD 11,272.80 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Inhalation & Nasal Sprays Generic Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Indication, the market was studied across Allergic Rhinitis, Asthma, and COPD.
Based on Age Group, the market was studied across Adults, Children 2 to 5, and Children 6 to 12.
Based on Class, the market was studied across Allergy Blocker, Anticholinergic, Antihistamine, Decongestant, Mast Cell Inhibitor, and Nasal Steroid.
Based on Route, the market was studied across Inhalation, Nasal Spray, and Tropical Lotion.
Based on Distrubution Channel, the market was studied across Hospital Medical Store, Online Pharmacy, and Pharmacy Retail.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Connecticut, Florida, Illinois, Maryland, Minnesota, New Jersey, New York, Ohio, Pennsylvania, Texas, and Washington. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Inhalation & Nasal Sprays Generic Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Inhalation & Nasal Sprays Generic Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Inhalation & Nasal Sprays Generic Drugs Market, including AbbVie Inc., Akorn, Inc., Altaire Pharmaceuticals Inc., Apotex Inc., AstraZeneca PLC, Beximco Pharmaceuticals Ltd., Catalent Pharma Solutions, Inc., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Nephron Pharmaceuticals Corporation, Perrigo Company PLC, Preferred Pharmaceuticals, Inc., Sandoz International GmbH, Sheffield Pharmaceuticals, LLC, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Inhalation & Nasal Sprays Generic Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Inhalation & Nasal Sprays Generic Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Inhalation & Nasal Sprays Generic Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Inhalation & Nasal Sprays Generic Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Inhalation & Nasal Sprays Generic Drugs Market?
6. What is the market share of the leading vendors in the Global Inhalation & Nasal Sprays Generic Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Inhalation & Nasal Sprays Generic Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Low Cost Involved with Generic Prescription Drugs
5.1.1.2. Increasing Prevalence of Respiratory Diseases
5.1.1.3. Significant Adoption of Nebulizers for Children
5.1.2. Restraints
5.1.2.1. Stringent Regulations For Generic Drugs
5.1.3. Opportunities
5.1.3.1. Patent Expiry of Blockbuster Drugs and Increasing FDA Approvals
5.1.3.2. Growing Investments from Pharmaceutical Companies for R&D
5.1.4. Challenges
5.1.4.1. Pricing Pressure due to Presence of Multiple Players in the Segment
5.2. Cumulative Impact of COVID-19
6. Inhalation & Nasal Sprays Generic Drugs Market, by Indication
6.1. Introduction
6.2. Allergic Rhinitis
6.3. Asthma
6.4. COPD
7. Inhalation & Nasal Sprays Generic Drugs Market, by Age Group
7.1. Introduction
7.2. Adults
7.3. Children 2 to 5
7.4. Children 6 to 12
8. Inhalation & Nasal Sprays Generic Drugs Market, by Class
8.1. Introduction
8.2. Allergy Blocker
8.3. Anticholinergic
8.4. Antihistamine
8.5. Decongestant
8.6. Mast Cell Inhibitor
8.7. Nasal Steroid
9. Inhalation & Nasal Sprays Generic Drugs Market, by Route
9.1. Introduction
9.2. Inhalation
9.3. Nasal Spray
9.4. Tropical Lotion
10. Inhalation & Nasal Sprays Generic Drugs Market, by Distrubution Channel
10.1. Introduction
10.2. Hospital Medical Store
10.3. Online Pharmacy
10.4. Pharmacy Retail
11. Americas Inhalation & Nasal Sprays Generic Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Inhalation & Nasal Sprays Generic Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Inhalation & Nasal Sprays Generic Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. AbbVie Inc.
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Akorn, Inc.
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Altaire Pharmaceuticals Inc.
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Apotex Inc.
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. AstraZeneca PLC
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Beximco Pharmaceuticals Ltd.
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Catalent Pharma Solutions, Inc.
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Chiesi Farmaceutici S.p.A.
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Cipla Limited
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Hikma Pharmaceuticals PLC
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Nephron Pharmaceuticals Corporation
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Perrigo Company PLC
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Preferred Pharmaceuticals, Inc.
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Sandoz International GmbH
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Sheffield Pharmaceuticals, LLC
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Sun Pharmaceutical Industries Ltd.
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Teva Pharmaceutical Industries Ltd.
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Viatris Inc.
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing